Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The trial is a phase IV clinical trial investigating the impact of Liraglutide on endothelial
function and microvascular blood flow in 44 patients with type 2 diabetes mellitus aged 30-65
and HbA1c ranging from ≥ 5.5% ≤ 7.0%. The patients will be randomized into two study arms,
one arm will be treated with Metformin monotherapy, the second arm will be treated with
Metformin and Liraglutide at an increasing dose (0.6 mg/day to 1.8 mg/day.)
Phase:
Phase 4
Details
Lead Sponsor:
ikfe-CRO GmbH
Collaborators:
IKFE Institute for Clinical Research and Development Novo Nordisk A/S